Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.122
-0.020 (-1.75%)
At close: Jul 25, 2025, 4:00 PM
1.160
+0.038 (3.39%)
After-hours: Jul 25, 2025, 6:54 PM EDT
Enlivex Therapeutics Employees
Enlivex Therapeutics had 71 employees as of December 31, 2021. The number of employees increased by 21 or 42.00% compared to the previous year.
Employees
71
Change (1Y)
21
Growth (1Y)
42.00%
Revenue / Employee
n/a
Profits / Employee
-$201,775
Market Cap
26.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 71 | 21 | 42.00% |
| Dec 31, 2020 | 50 | 14 | 38.89% |
| Dec 31, 2019 | 36 | 5 | 16.13% |
| Dec 31, 2018 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENLV News
- 6 weeks ago - Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - GlobeNewsWire
- 2 months ago - Enlivex Selected to Present at Israeli BioMed 2025 Conference - GlobeNewsWire
- 3 months ago - Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress - GlobeNewsWire
- 3 months ago - Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis - GlobeNewsWire
- 4 months ago - Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - GlobeNewsWire
- 4 months ago - Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - GlobeNewsWire
- 5 months ago - Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - GlobeNewsWire
- 5 months ago - Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis - GlobeNewsWire